Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

OPGN

Opgen Inc

Apr 16 • 09:53AM ET

0.6227

Dollar change -0.0353
Percentage change -5.36	%

Healthcare • Medical Devices • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-6.52	Insider Own	0.41%	Shs Outstand	10.01M	Perf Week	-12.31%
Market Cap	6.23M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	9.97M	Perf Month	29.46%
Income	-26.16M	PEG	-	EPS next Q	-	Inst Own	2.68%	Short Float	22.32%	Perf Quarter	58.49%
Sales	3.07M	P/S	2.03	EPS this Y	-	Inst Trans	-	Short Ratio	1.29	Perf Half Y	-24.25%
Book/sh	0.27	P/B	2.33	EPS next Y	-	ROA	-102.41%	Short Interest	2.23M	Perf Year	-45.38%
Cash/sh	0.03	P/C	21.49	EPS next 5Y	-	ROE	-314.91%	52W Range	0.17 - 3.84	Perf YTD	48.26%
Dividend Est.	-	P/FCF	-	EPS past 5Y	67.03%	ROI	-475.06%	52W High	-83.78%	Beta	-0.68
Dividend TTM	-	Quick Ratio	0.18	Sales past 5Y	-	Gross Margin	6.62%	52W Low	277.39%	ATR (14)	0.08
Dividend Ex-Date	-	Current Ratio	0.28	EPS Y/Y TTM	64.39%	Oper. Margin	-597.83%	RSI (14)	50.58	Volatility	8.69% 15.15%
Employees	-	Debt/Eq	4.68	Sales Y/Y TTM	-7.28%	Profit Margin	-852.11%	Recom	3.00	Target Price	3.00
Option/Short	No / Yes	LT Debt/Eq	1.06	EPS Q/Q	92.18%	Payout	-	Rel Volume	0.21	Prev Close	0.66
Sales Surprise	-22.33%	EPS Surprise	-6.98%	Sales Q/Q	55.78%	Earnings	Nov 14 AMC	Avg Volume	1.73M	Price	0.62
SMA20	-1.48%	SMA50	18.22%	SMA200	30.41%	Trades		Volume	38,579	Change	-5.36%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-01-19	Initiated	Alliance Global Partners	Buy	$2.30
Feb-07-18	Reiterated	H.C. Wainwright	Buy	$1 → $9
Jun-29-16	Initiated	Rodman & Renshaw	Buy	$2.50

Mar-25-24 04:05PM	OpGen Announces Acquisition of Preferred Stock by David Lazar (GlobeNewswire)
Mar-08-24 04:20PM	Lineage Cell Therapeutics, Inc. (AMEX:LCTX) Q4 2023 Earnings Call Transcript (Insider Monkey) +6.87%
Nov-14-23 04:30PM	OpGen Reports Third Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire) -7.37%
Oct-12-23 12:32PM	OpGen Enters Into Warrant Inducement Transaction for up to $11.2 Million in Gross Proceeds (GlobeNewswire) +173.81%
11:52AM	ChatGPT Parent OpenAI Aims At Budget-Friendly AI Innovations, Novo Nordisk's Popular Diabetes Drug Ozempic Faces Counterfeit Threat in Germany: Today's Top Stories (Benzinga)
07:57AM	Loading…
07:57AM	Why Is OpGen (OPGN) Stock Up 540% Today? (InvestorPlace)
Sep-29-23 08:22AM	Why Is OpGen (OPGN) Stock Up 115% Today? (InvestorPlace) +99.30%
Aug-13-23 07:46AM	OpGen, Inc. (NASDAQ:OPGN) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-11-23 06:18AM	Q2 2023 OpGen Inc Earnings Call (Thomson Reuters StreetEvents) -24.16%
Aug-10-23 04:15PM	OpGen Reports Second Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire) -23.42%
Aug-07-23 07:30AM	OpGens Subsidiary Ares Genetics Releases New Features to its AREScloud Offering (GlobeNewswire)
Aug-03-23 08:00AM	OpGens Subsidiary Curetis and FIND Extend R&D Collaboration Agreement (GlobeNewswire)
07:30AM	OpGen to Provide Business Update and Financial Results for the Second Quarter 2023 on August 10th at 4:30 p.m. Eastern Time (GlobeNewswire)
Jul-19-23 07:30AM	OpGens Subsidiary Curetis Meets Milestones of Extended and Expanded R&D Collaboration with FIND (GlobeNewswire)
Jun-26-23 07:30AM	OpGen Subsidiary Ares Genetics Successfully Maintains Key Patent under Opposition in Europe (GlobeNewswire)
07:30AM	Loading…
Jun-22-23 07:30AM	OpGens Subsidiary Curetis Receives Batch of Ten New C-Series Unyvero A30 Instruments (GlobeNewswire)
Jun-20-23 07:30AM	OpGen Presents Unyvero Urinary Tract Infection Panel Trial Results at ASM Microbe 2023 Conference (GlobeNewswire) -5.00%
May-16-23 06:43AM	Q1 2023 OpGen Inc Earnings Call (Thomson Reuters StreetEvents)
May-15-23 04:15PM	OpGen Reports First Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire) -6.91%
May-08-23 07:30AM	OpGen to Provide Business Update and Financial Results for the First Quarter 2023 on May 15th at 4:30 p.m. Eastern Time (GlobeNewswire)
May-04-23 04:30PM	OpGen Announces Closing of $3.5 Million Public Offering (GlobeNewswire) +6.05%
May-01-23 09:00PM	OpGen Announces Pricing of $3.5 Million Public Offering (GlobeNewswire)
Apr-26-23 04:30PM	OpGens Subsidiary Curetis Meets All Remaining Key Milestones in R&D Collaboration with FIND (GlobeNewswire) -7.14%
Apr-19-23 08:38AM	Zacks.com featured highlights include Disney, Casey's General Stores, OpGen, Accelerate Diagnostics and Nektar Therapeutics (Zacks)
Apr-18-23 04:30PM	OpGen Enters Into Distribution Agreement for Unyvero in the U.S. with Fisher Healthcare (GlobeNewswire) -13.02%
07:30AM	OpGen Submits De Novo request to the U.S. FDA for Unyvero Urinary Tract Infection Panel (GlobeNewswire)
Apr-05-23 07:30AM	OpGens Subsidiary Curetis Signs Expansion of R&D Collaboration with FIND (GlobeNewswire)
Apr-03-23 07:30AM	OpGens Subsidiary Curetis Meets Milestones in Collaborative Research Project with InfectoGnostics (GlobeNewswire)
Apr-01-23 10:44PM	OpGen, Inc. (NASDAQ:OPGN) Q4 2022 Earnings Call Transcript (Insider Monkey)
08:57AM	OpGen Full Year 2022 Earnings: Misses Expectations (Simply Wall St.)
02:25PM	Loading…
Mar-30-23 02:25PM	CORRECTION OpGen Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update (GlobeNewswire) -13.24%
Mar-29-23 04:15PM	OpGen Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update (GlobeNewswire) -6.85%
Mar-22-23 07:30AM	OpGen to Provide Business Update and Financial Results for the Fourth Quarter and Full Year 2022 on March 29th at 4:30 p.m. Eastern Time (GlobeNewswire)
Mar-01-23 07:30AM	OpGen Subsidiary Ares Genetics Announces its Move to New Vienna Location and Provides Update on Business Growth (GlobeNewswire)
Feb-17-23 07:30AM	OpGen Announces Exercise of All Prefunded Warrants (GlobeNewswire)
Jan-26-23 07:30AM	OpGen subsidiary Ares Genetics announces granting of key patent in China (GlobeNewswire)
Jan-18-23 07:30AM	OpGen Provides Preliminary Unaudited Revenue for FY 2022 and Business Update (GlobeNewswire) -6.75%
Jan-17-23 07:30AM	OpGen Subsidiary Curetis Meets Several Key Milestones in FIND Collaboration Project (GlobeNewswire)
Jan-11-23 04:30PM	OpGen Announces Closing of $7.5 Million Public Offering (GlobeNewswire)
Jan-06-23 08:00PM	OpGen Announces Pricing of $7.5 Million Public Offering (GlobeNewswire) -5.36%
Jan-04-23 04:30PM	OpGen Announced 1-for-20 Reverse Stock Split (GlobeNewswire)
Dec-13-22 09:44AM	Penny Stock OpGen Surges After UTI Panel Test Meets Primary Goal In Clinical Trial (Benzinga) +84.80%
07:30AM	OpGen Announces Positive Top Line Data from Clinical Trial for Unyvero Urinary Tract Infection Panel (GlobeNewswire)
Nov-10-22 04:10PM	OpGen Reports Third Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire)
Oct-27-22 07:30AM	OpGen to Provide Business Update and Financial Results for the Third Quarter 2022 on November 10th at 4:30 p.m. Eastern Standard Time (GlobeNewswire)
07:30AM	OpGen Announces Preliminary Unaudited Revenue and Cash Position for Third Quarter 2022 and Provides Business Update (GlobeNewswire)
Oct-25-22 07:30AM	OpGen Subsidiary Curetis and BioVersys Sign Collaboration Agreement for Clinical Trial Support (GlobeNewswire)
Oct-03-22 04:20PM	OpGen Announces Closing of $3.38 Million Registered Direct Offering (GlobeNewswire) +8.32%
07:30AM	OpGen Announces Successful Completion of Clinical Trial Enrollment for Unyvero Urinary Tract Infection Panel (GlobeNewswire)
Sep-30-22 08:38AM	OpGen Announces $3.38 Million Registered Direct Offering (GlobeNewswire) -24.02%
Sep-20-22 07:30AM	OpGen Subsidiary Curetis and FIND Sign R&D Collaboration Agreement for Unyvero A30 RQ Platform (GlobeNewswire)
Sep-06-22 07:30AM	OpGen Announces Participation at the H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire) -5.77%
Aug-31-22 07:30AM	Nasdaq Grants OpGen 180-Day Extension to Meet Minimum Bid Price Requirement (GlobeNewswire)
Aug-25-22 07:30AM	OpGen Launches Ares Sequencing Services in the U.S. from its Rockville, Maryland Laboratory (GlobeNewswire)
Aug-11-22 04:15PM	OpGen Reports Second Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire) +5.00%
Jul-28-22 07:30AM	OpGen to Provide Business Update and Financial Results for the Second Quarter 2022 on August 11th at 4:30 p.m. Eastern Time (GlobeNewswire)
Jul-26-22 07:30AM	OpGen Subsidiary Ares Genetics GmbH Enters into Collaboration Agreement with the Belgian National Reference Centre for Invasive S. pneumoniae at UZ Leuven (GlobeNewswire)
Jul-08-22 07:30AM	OpGen Announces Preliminary Unaudited Revenue and Cash Position for Second Quarter 2022 and Provides Business Update (GlobeNewswire)
Jun-27-22 11:22PM	Toshiba Shareholders Approve Proposal to Invite Activist Investors to Board (MarketWatch)
Jun-22-22 08:00AM	OpGen Announces Publication of Results of Unyvero Hospitalized Pneumonia (HPN) Panel for Detection of Bacterial Respiratory Tract Pathogens from Serial Specimens Collected from Hospitalized COVID-19 Patients (GlobeNewswire) +6.94%
07:30AM	OpGen Announces 1,000th Patient Sample Enrolled in Clinical Trial for Unyvero Urinary Tract Infection Panel (GlobeNewswire)
Jun-09-22 07:30AM	OpGen Subsidiary Curetis and Leader Life Sciences Enter into Unyvero Distribution Partnership for U.A.E. and Qatar (GlobeNewswire)
May-26-22 07:30AM	OpGen Announces Publication of Results from Major Clinical Study Using Unyvero Hospitalized Pneumonia (HPN) Panel in the Lancet Respiratory Medicine (GlobeNewswire) +27.21%
May-12-22 05:35PM	OpGen, Inc. (OPGN) Reports Q1 Loss, Lags Revenue Estimates (Zacks) +12.52%
04:15PM	OpGen Reports First Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire)
Apr-28-22 07:30AM	OpGen to Provide Business Update and Financial Results for the First Quarter 2022 on May 12th at 4:30 p.m. Eastern Time (GlobeNewswire)
Apr-25-22 07:30AM	OpGens Subsidiary Curetis and European Investment Bank Plan to Restructure Debt Repayment (GlobeNewswire) -6.09%
Apr-20-22 07:30AM	OpGens Subsidiary Ares Genetics Commercially Launches New Sequencing and Analysis Services Globally (GlobeNewswire)
Apr-06-22 07:30AM	OpGens subsidiary Ares Genetics provides update on collaboration agreement to drive cutting-edge digital solutions in global fight against antimicrobial resistance (AMR) (GlobeNewswire)
Apr-05-22 07:30AM	OpGen Announces Interim Analysis Results from Clinical Trial for Unyvero Urinary Tract Infection Panel (GlobeNewswire)
Mar-29-22 07:25PM	OpGen, Inc. (OPGN) Reports Q4 Loss, Tops Revenue Estimates (Zacks) +10.68%
04:05PM	OpGen Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update (GlobeNewswire)
Mar-24-22 07:05PM	CoDiagnostics, Inc. (CODX) Q4 Earnings Beat Estimates (Zacks)
Mar-15-22 07:30AM	OpGen to Provide Business Update and Financial Results for the Fourth Quarter and Full Year 2021 on March 29th at 4:30 p.m. Eastern Time (GlobeNewswire)
Feb-28-22 07:55PM	Surgery Partners (SGRY) Misses Q4 Earnings and Revenue Estimates (Zacks)
Feb-10-22 04:30PM	OpGen Announces Publication of Results from the Acuitas AMR Gene Panel Multicenter Clinical Trial in the Journal of Clinical Microbiology (GlobeNewswire)
07:30AM	OpGen Announces Successful Completion of Unyvero A30 Development Milestone (GlobeNewswire)
Jan-18-22 07:30AM	OpGen to Participate in Edison Groups Global Healthcare Open House Virtual Conference from January 25-27th, 2022 (GlobeNewswire)
Jan-10-22 07:30AM	OpGen Announces Preliminary Unaudited Revenue for Fiscal 2021 and Provides Business Update (GlobeNewswire)
Dec-14-21 07:30AM	OpGen subsidiary Ares Genetics announces the strategic expansion of ARESdb proprietary contents (GlobeNewswire)
Dec-08-21 04:30PM	OpGen Announces Results of Special Meeting of Stockholders (GlobeNewswire)
Nov-30-21 08:45AM	OpGen Subsidiary Ares Genetics Announces Strategic Database Access Transaction (GlobeNewswire)
Nov-11-21 04:05PM	OpGen Reports Third Quarter 2021 Financial Results and Provides Business Update (GlobeNewswire)
Nov-04-21 03:01PM	OpGen, Inc. (OPGN) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
07:30AM	OpGen Appoints Albert Weber as Chief Financial Officer (GlobeNewswire)
07:30AM	OpGen Announces Special Meeting of Stockholders to Vote on Proposed Increase to Number of Authorized Shares of Common Stock (GlobeNewswire)
Oct-28-21 07:30AM	OpGen to Provide Business Update and Financial Results for the Third Quarter 2021 on November 11th at 4:30 p.m. Eastern Time (GlobeNewswire)
Oct-21-21 07:30AM	OpGen Subsidiary Ares Genetics Launches AREScloud (GlobeNewswire)
Oct-18-21 04:30PM	OpGen Announces Closing of $15 Million Registered Direct Offering (GlobeNewswire)
Oct-14-21 08:00AM	OpGen Announces $15 Million Registered Direct Offering (GlobeNewswire)
Oct-05-21 05:17AM	44 Biggest Movers From Yesterday (Benzinga) -19.05%
Oct-04-21 02:59PM	Rockville biotech lands federal approval for superbug testing system (American City Business Journals) +6.52%
12:16PM	Mid-Day Market Update: Nasdaq Down 2%; Xenon Pharmaceuticals Shares Jump (Benzinga)
12:06PM	30 Stocks Moving In Monday's Mid-Day Session (Benzinga)
09:08AM	5 Top Stock Gainers for Monday: Ford, General Motors, Xenon (TheStreet.com)
08:46AM	OpGen Stock Gains On FDA Approval, Interim Q3 Sales (Benzinga)
07:46AM	OpGen stock rockets after upbeat revenue update (MarketWatch)
07:30AM	OpGen Receives FDA Clearance for Acuitas® AMR Gene Panel (GlobeNewswire)
07:30AM	OpGen Provides Business Update and Announces Preliminary Unaudited Revenue and Cash Position for Third Quarter 2021 (GlobeNewswire)
07:00AM	18 Stocks Moving in Monday's Pre-Market Session (Benzinga)

OpGen, Inc. is a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease. It engages in the development of molecular information products and services for global healthcare settings. The firm's also offers guidance to clinicians about life threatening infections, improving patient outcomes, and decreasing the spread of infections caused by multidrug-resistant microorganisms. Its products include Unyvero, Acuitas AMR Gene Panel and Acuitas Lighthouse, and the ARES Technology Platform including ARESdb, using NGS technology and AI-powered bioinformatics solutions for antibiotic response prediction. The company was founded on January 22, 2001 and is headquartered in Gaithersburg, MD.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

OPGN

Opgen Inc

Upgrade your FINVIZ experience